7‑Hydroxymitragynine Is an Active Metabolite
of Mitragynine and a Key Mediator of Its Analgesic Effects
Version 2 2019-06-26, 07:32
Version 1 2019-05-29, 12:07
Posted on 2019-06-26 - 07:32
Mitragyna speciosa, more commonly known as kratom,
is a plant native to Southeast Asia, the leaves of which have been
used traditionally as a stimulant, analgesic, and treatment for opioid
addiction. Recently, growing use of the plant in the United States
and concerns that kratom represents an uncontrolled drug with potential
abuse liability, have highlighted the need for more careful study
of its pharmacological activity. The major active alkaloid found in
kratom, mitragynine, has been reported to have opioid agonist and
analgesic activity in vitro and in animal models, consistent with
the purported effects of kratom leaf in humans. However, preliminary
research has provided some evidence that mitragynine and related compounds
may act as atypical opioid agonists, inducing therapeutic effects
such as analgesia, while limiting the negative side effects typical
of classical opioids. Here we report evidence that an active metabolite
plays an important role in mediating the analgesic effects of mitragynine.
We find that mitragynine is converted in vitro in both mouse and human
liver preparations to the much more potent mu-opioid receptor agonist
7-hydroxymitragynine and that this conversion is mediated by cytochrome
P450 3A isoforms. Further, we show that 7-hydroxymitragynine is formed
from mitragynine in mice and that brain concentrations of this metabolite
are sufficient to explain most or all of the opioid-receptor-mediated
analgesic activity of mitragynine. At the same time, mitragynine is
found in the brains of mice at very high concentrations relative to
its opioid receptor binding affinity, suggesting that it does not
directly activate opioid receptors. The results presented here provide
a metabolism-dependent mechanism for the analgesic effects of mitragynine
and clarify the importance of route of administration for determining
the activity of this compound. Further, they raise important questions
about the interpretation of existing data on mitragynine and highlight
critical areas for further research in animals and humans.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Kruegel, Andrew
C.; Uprety, Rajendra; Grinnell, Steven G.; Langreck, Cory; Pekarskaya, Elizabeth A.; Rouzic, Valerie Le; et al. (2019). 7‑Hydroxymitragynine Is an Active Metabolite
of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Publications. Collection. https://doi.org/10.1021/acscentsci.9b00141
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (13)
AK
Andrew
C. Kruegel
RU
Rajendra Uprety
SG
Steven G. Grinnell
CL
Cory Langreck
EP
Elizabeth A. Pekarskaya
VR
Valerie Le Rouzic
MA
Michael Ansonoff
MM
Madalee M. Gassaway
JE
John E. Pintar
GP
Gavril W. Pasternak
JJ
Jonathan A. Javitch
SM
Susruta Majumdar
DS
Dalibor Sames
KEYWORDS
opioid agonistsopioid receptor binding affinityanimal modelsabuse liabilityreport evidenceopioid receptorsside effectsmetabolism-dependent mechanismActive Metaboliteliver preparationsUnited Statesopioid addictionbrain concentrationsopioid agonistkratom leafcytochrome P 450 3mu-opioid receptor agonist 7- hydroxymitragynineAnalgesic Effects Mitragyna speciosaKey Mediator7- hydroxymitragynineSoutheast Asia